title: A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17β-estradiol for moderate to severe vasomotor symptoms in postmenopausal women.
abstract: OBJECTIVE
  This study aims to investigate the efficacy and safety of daily drospirenone/17β-estradiol in two low-dose combinations (0.25 mg/0.5 mg and 0.5 mg/0.5 mg, respectively) versus 17β-estradiol (0.3 mg) or placebo in postmenopausal women with moderate to severe vasomotor symptoms.
  
  
  METHODS
  Seven hundred thirty-five postmenopausal women aged 40 years or older who experienced a minimum of 7 to 8 moderate to severe hot flushes per day, or 50 to 60 moderate to severe hot flushes per week, participated in a 12-week, double-blind, randomized, placebo-controlled study. The primary efficacy variables were mean changes from baseline to weeks 4 and 12 in the weekly frequency and weekly mean daily severity of moderate to severe hot flushes recorded daily by the participants on diary cards.
  
  
  RESULTS
  All active treatments were significantly more effective than placebo for the primary efficacy variables for drospirenone/17β-estradiol (P < 0.0001), and for 17β-estradiol (P < 0.01) at 4 and 12 weeks. Efficacy was greater for both low-dose drospirenone/17β-estradiol combinations versus the lower-dose 17β-estradiol. Change in vaginal pH and vaginal maturation index showed significant improvements (with P values versus placebo of <0.0001 and P ≤ 0.0028, respectively), and exploratory analysis of the Clinical Global Impressions scale score indicated an overall satisfaction of women with active treatments. All active treatments were generally well tolerated with low rates of adverse event-related dropouts, and the safety profile of drospirenone/17β-estradiol in both low-dose combinations was consistent with previous studies.
  
  
  CONCLUSIONS
  Drospirenone 0.25 mg/17β-estradiol 0.5 mg is concluded to be the lowest dose with demonstrated efficacy in the treatment of postmenopausal women with moderate to severe vasomotor symptoms.
authors: From the 1Clinical Research Center, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA; 2Bayer Pharma AG, Berlin, Germany; and 3Gynecology, Obstetrics, and Reproductive Medicine, University Medical School of Saarland, Homburg/Saar, Germany.
authors: David F
authors: DF
authors: Archer
authors: Thomas
authors: T
authors: Schmelter
authors: Matthias
authors: M
authors: Schaefers
authors: Christoph
authors: C
authors: Gerlinger
authors: Kerstin
authors: K
authors: Gude
mesh_terms: D000328:Adult; D000736:Androstenes / Q000008:administration & dosage* / Q000009:adverse effects; D001706:Biopsy; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004717:Endometrium / Q000473:pathology; D004958:Estradiol / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D019584:Hot Flashes / Q000188:drug therapy*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008875:Middle Aged; D010919:Placebos; D017698:Postmenopause; D014621:Vagina; D014626:Vaginal Smears
chemical_list: D000736:Androstenes; D010919:Placebos; D004958:Estradiol; C035144:drospirenone